Home / Health / Obesity Pill: Cheaper, Needle-Free Future for UK?
Obesity Pill: Cheaper, Needle-Free Future for UK?
15 Jan
Summary
- UK is reviewing an oral version of the popular GLP-1 obesity drug.
- A pill could offer a cheaper, needle-free alternative to injections.
- Experts stress obesity is a chronic disease requiring lifelong management.

A potential breakthrough in obesity treatment is on the horizon for the UK, as the Medicines and Healthcare products Regulatory Agency (MHRA) is currently reviewing a licence application for an oral version of semaglutide. Injectable GLP-1 drugs have seen a surge in popularity, with around 1.6 million adults using them in the past year. However, the high cost of these injections, ranging from £100 to £300, has been a significant barrier for many accessing them privately.
Medical experts are optimistic that the approval of a pill form in the US could lead to a more affordable oral option in the UK. This could pave the way for lifelong management of obesity, similar to treatments for other chronic conditions like high blood pressure or diabetes. For individuals with a fear of needles, this oral medication offers a crucial alternative, removing a significant obstacle to treatment. Experts emphasize that obesity is a chronic disease, not a choice, and managing it lifelong is essential for reducing mortality and preventing severe health complications.




